Preliminary Results Of An Open-Label, Multicentric, Phase Ib/II Study To Assess The Safety And Efficacy Of Asidna, A Dna Repair Inhibitor, In Addition To Parp Inhibitor In Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Parpi For At Least 6 Months (Revocan)
Asidna
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Preliminary Results Of An Open-Label, Multicentric, Phase Ib/II Study To Assess The Safety And Efficacy Of Asidna, A Dna Repair Inhibitor, In Addition To Parp Inhibitor In Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Parpi For At Least 6 Months (Revocan) ### Output: Asidna